Close Menu

non-small cell lung cancer

Clinical Care Options, a developer of continuing education and medical decision support resources, has launched a web-based tool to help oncologists figure out which lung cancer patients may benefit from molecularly guided personalized treatments.

Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlo

Transgenomic this week announced its second collaboration with a university medical center to evaluate the use of its Ice-Cold-PCR technology for blood-based mutation detection in cancer.

NEW YORK (GenomeWeb News) – Transgenomic said today that it is collaborating with New York University Langone Medical Center to use its Ice-Cold-PCR technology to study the molecular basis of non-small cell lung cancer and therapeutic response to existing and novel NSCLC therapies.

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.

Biodesix this week presented data indicating that a proteomic signature identified using the company's ProTS mass spec-based system can identify pancreatic cancer patients likely to respond to treatment with GlobeImmune's GI-4000 therapy.

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.